Integer (ITGR) to Release Earnings on Thursday

Integer (NYSE:ITGR) will likely be releasing its Q4 2025 results before the market opens on Thursday, February 19th. Analysts expect the company to announce earnings of $1.70 per share and revenue of $462.7250 million for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, February 19, 2026 at 9:00 AM ET.

Integer Stock Performance

Shares of ITGR stock opened at $87.26 on Thursday. The stock has a fifty day moving average price of $80.81 and a 200 day moving average price of $89.22. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.45 and a current ratio of 3.71. The stock has a market cap of $3.06 billion, a PE ratio of 36.51, a P/E/G ratio of 0.79 and a beta of 0.77. Integer has a 1 year low of $62.00 and a 1 year high of $144.76.

Integer declared that its Board of Directors has authorized a share repurchase program on Tuesday, November 4th that allows the company to buyback $200.00 million in outstanding shares. This buyback authorization allows the medical equipment provider to buy up to 8.3% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s leadership believes its stock is undervalued.

Analyst Ratings Changes

Several brokerages have recently issued reports on ITGR. Truist Financial boosted their price objective on shares of Integer from $86.00 to $95.00 and gave the company a “buy” rating in a research note on Thursday, December 18th. Citigroup lifted their target price on shares of Integer from $69.00 to $75.00 and gave the company a “neutral” rating in a report on Thursday, December 11th. Piper Sandler lowered their target price on Integer from $155.00 to $82.00 and set an “overweight” rating for the company in a research note on Friday, October 24th. Benchmark reissued a “hold” rating on shares of Integer in a research report on Friday, October 24th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Integer in a report on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $98.38.

Hedge Funds Weigh In On Integer

A number of hedge funds and other institutional investors have recently bought and sold shares of ITGR. State Street Corp lifted its stake in Integer by 1.0% in the second quarter. State Street Corp now owns 1,326,050 shares of the medical equipment provider’s stock valued at $163,064,000 after buying an additional 13,540 shares during the last quarter. Viking Global Investors LP raised its holdings in shares of Integer by 9.1% during the second quarter. Viking Global Investors LP now owns 1,283,965 shares of the medical equipment provider’s stock valued at $157,889,000 after buying an additional 106,692 shares during the last quarter. Alliancebernstein L.P. boosted its position in shares of Integer by 885.1% during the second quarter. Alliancebernstein L.P. now owns 1,106,091 shares of the medical equipment provider’s stock worth $136,016,000 after buying an additional 993,810 shares during the period. Bamco Inc. NY grew its holdings in Integer by 9.9% in the 2nd quarter. Bamco Inc. NY now owns 422,258 shares of the medical equipment provider’s stock worth $51,925,000 after buying an additional 38,203 shares in the last quarter. Finally, Raymond James Financial Inc. increased its position in Integer by 14.3% in the 3rd quarter. Raymond James Financial Inc. now owns 330,317 shares of the medical equipment provider’s stock valued at $34,132,000 after acquiring an additional 41,209 shares during the period. 99.29% of the stock is currently owned by institutional investors and hedge funds.

About Integer

Integer Holdings Corporation (NYSE: ITGR) is a global provider of outsourced medical device design, development and manufacturing solutions. The company partners with leading medical technology firms to deliver complex components, subsystems and finished devices across a range of therapeutic areas. Its services encompass concept and product design, precision machining, microelectronic assembly, terminal sterilization and regulatory support, enabling customers to accelerate time to market and optimize product performance.

Integer’s product portfolio is organized into two core segments: Advanced Delivery and MedTech.